Brookfield Corp’s Charles River Laboratories CRL Stock Holding History

Brookfield Corp’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36,187	Closed	-$7.89M	–	683
2022 Q4	$7.89M	Sell	36,187 -13,895	-28%	-$3.03M	0.03%	181
2022 Q3	$9.86M	Buy	50,082 +16,473	+49%	+$3.56M	0.04%	161
2022 Q2	$7.19M	Buy	33,609 +5,406	+19%	+$1.32M	0.03%	196
2022 Q1	$8.01M	Buy	28,203 +16,096	+133%	+$4.96M	0.03%	187
2021 Q4	$4.56M	Buy	12,107 +4,308	+55%	+$1.67M	0.02%	232
2021 Q3	$3.22M	Buy	7,799 +1,245	+19%	+$517K	0.01%	280
2021 Q2	$2.42M	Buy	+6,554	New	+$2.19M	0.01%	330
2020 Q4	–	Sell	-8,562	Closed	-$1.94M	–	455
2020 Q3	$1.94M	Buy	+8,562	New	+$1.78M	0.01%	249

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Brookfield Corp's CRL Position: Q1 2023 in Review

Brookfield Corp sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 36,187 shares — an estimated $7.89M sold.

Brookfield Corp first reported a position in CRL in Q3 2020 and held it in 8 quarters. The position peaked at $9.86M in Q3 2022. 621 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

Brookfield Corp reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 36,187 Charles River Laboratories shares in Q1 2023, an estimated $7.89M.
Brookfield Corp first reported a position in Charles River Laboratories in Q3 2020 and held it in 8 quarters.
Brookfield Corp's Charles River Laboratories position peaked at $9.86M in Q3 2022.
621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.